ÂÜÀòÂÒÂ×

Paul Schneider is an accomplished financial executive with extensive experience in the biotechnology and pharmaceuticals sectors. Currently serving as Chief Financial Officer at Spur Therapeutics since May 2022, Paul previously held senior roles, including Senior Vice President of Finance & Operations at Exo Therapeutics and Senior Vice President of Finance at Casebia Therapeutics. At Aegerion Pharmaceuticals, Paul contributed in various capacities, including Vice President of FP&A and Vice President of Patient and Market Access, where leadership in global financial operations and patient support services was crucial. Earlier career milestones include significant roles at Systagenix Wound Management, Shire Human Genetic Therapies, Transkaryotic Therapies, and Coopers & Lybrand. Paul Schneider holds a Bachelor of Science in Accounting from Boston College.